Overview

A Study of CS3006 in Subjects With Locally Advanced or Metastatic Solid Tumors

Status:
Completed
Trial end date:
2020-06-18
Target enrollment:
Participant gender:
Summary
This is a multicenter, open label, dose escalation & expansion phase I study to evaluate the clinical safety, tolerability, PK, and preliminary efficacy of CS3006.
Phase:
Phase 1
Details
Lead Sponsor:
CStone Pharmaceuticals